Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy
- 30 June 2009
- journal article
- review article
- Published by Elsevier BV in Drug Resistance Updates
- Vol. 12 (3), 65-73
- https://doi.org/10.1016/j.drup.2009.03.001
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Targeted therapies in breast cancer: Where are we now?European Journal of Cancer, 2008
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- The RSK family of kinases: emerging roles in cellular signallingNature Reviews Molecular Cell Biology, 2008
- Class I PI3K in oncogenic cellular transformationOncogene, 2008
- Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatmentDrug Resistance Updates, 2008
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsDrug Resistance Updates, 2008
- Differential regulation and properties of MAPKsOncogene, 2007
- Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacyBritish Journal of Cancer, 2007
- Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cellsInternational Journal of Cancer, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004